CVL-354

CVL-354 is a drug candidate that was developed by Convergence Pharmaceuticals, a company specializing in the development of novel and high value analgesic medicines for the treatment of chronic pain. CVL-354 is a potent and selective antagonist of the Kappa Opioid Receptor (KOR), a protein that plays a key role in the perception of pain.

History

CVL-354 was first synthesized and studied by Convergence Pharmaceuticals, a company that was later acquired by Biogen in 2015. The drug was developed as part of the company's efforts to create new treatments for chronic pain conditions.

Mechanism of Action

CVL-354 works by selectively blocking the Kappa Opioid Receptor. This receptor is one of the three types of opioid receptors found in the human body, the others being the Mu Opioid Receptor and the Delta Opioid Receptor. The KOR is involved in the perception of pain, mood, and consciousness. By blocking this receptor, CVL-354 is thought to reduce the sensation of pain.

Clinical Trials

CVL-354 has undergone several clinical trials to assess its safety and efficacy in treating chronic pain. In preclinical studies, the drug showed promising results, demonstrating potent analgesic effects without the side effects commonly associated with opioid drugs, such as addiction and respiratory depression.

Potential Applications

If approved, CVL-354 could be used to treat a variety of chronic pain conditions, including neuropathic pain, fibromyalgia, and osteoarthritis. The drug's unique mechanism of action could make it a valuable alternative to traditional opioid drugs, which are often associated with serious side effects and a high risk of addiction.

See Also

• Kappa Opioid Receptor
• Opioid Receptor
• Chronic Pain
• Neuropathic Pain
• Fibromyalgia
• Osteoarthritis